Trial Profile
LUME-Lung 3: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms LUME-Lung-3
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 29 Jun 2017 Status changed from active, no longer recruiting to completed.
- 06 Jan 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov.
- 06 Jan 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov.